Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1996 1
1998 2
1999 2
2000 1
2004 4
2005 2
2006 2
2007 3
2008 3
2009 1
2010 6
2011 6
2012 6
2013 7
2014 14
2015 16
2016 13
2017 14
2018 9
2019 18
2020 18
2021 19
2022 18
2023 8
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

173 results

Results by year

Filters applied: . Clear all
Page 1
Courage in a climate of fear.
Verghese A, Topol E. Verghese A, et al. Sci Transl Med. 2020 Nov 4;12(568):eabf2461. doi: 10.1126/scitranslmed.abf2461. Epub 2020 Oct 19. Sci Transl Med. 2020. PMID: 33077677 No abstract available.
Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma.
Böhm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A, Fitzpatrick A, Ennis D, Dowe T, Santos JL, Cook LS, Tinker AV, Le ND, Gilks CB, Singh N. Böhm S, et al. J Clin Oncol. 2015 Aug 1;33(22):2457-63. doi: 10.1200/JCO.2014.60.5212. Epub 2015 Jun 29. J Clin Oncol. 2015. PMID: 26124480
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.
Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Pápai Z, Meyer J, Nadel H, Randall RL, Deffenbaugh C, Nagarajan R, Brennan B, Letson GD, Teot LA, Goorin A, Baumhoer D, Kager L, Werner M, Lau CC, Sundby Hall K, Gelderblom H, Meyers P, Gorlick R, Windhager R, Helmke K, Eriksson M, Hoogerbrugge PM, Schomberg P, Tunn PU, Kühne T, Jürgens H, van den Berg H, Böhling T, Picton S, Renard M, Reichardt P, Gerss J, Butterfass-Bahloul T, Morris C, Hogendoorn PC, Seddon B, Calaminus G, Michelagnoli M, Dhooge C, Sydes MR, Bernstein M; EURAMOS-1 investigators. Bielack SS, et al. J Clin Oncol. 2015 Jul 10;33(20):2279-87. doi: 10.1200/JCO.2014.60.0734. Epub 2015 Jun 1. J Clin Oncol. 2015. PMID: 26033801 Free PMC article. Clinical Trial.
The Importance Of Being.
Verghese A. Verghese A. Health Aff (Millwood). 2016 Oct 1;35(10):1924-1927. doi: 10.1377/hlthaff.2016.0837. Health Aff (Millwood). 2016. PMID: 27702966
Introducing Global Health Law.
Gostin LO, Meier BM. Gostin LO, et al. J Law Med Ethics. 2019 Dec;47(4):788-793. doi: 10.1177/1073110519897794. J Law Med Ethics. 2019. PMID: 31957573 No abstract available.
Oral Treprostinil is Associated with Improved Survival in FREEDOM-EV and its Open-Label Extension.
Grünig E, Rahaghi F, Elwing J, Vizza CD, Pepke-Zaba J, Shen J, Yao H, Hage A, Rosenkranz S, Vonk M, Balasubramanian V, Yuanhua Y, Yu Z, Lordan J, Cadaret L, Grover R, Ousmanou A, Seaman S, Deng C, Broderick M, White RJ; FREEDOM-EV Investigators. Grünig E, et al. Adv Ther. 2024 Feb;41(2):618-637. doi: 10.1007/s12325-023-02711-x. Epub 2023 Dec 6. Adv Ther. 2024. PMID: 38055186 Free PMC article. Clinical Trial.
We repeated assessments including functional class and 6-min walk distance (6MWD) at 12-week intervals and measured N-terminal pro-brain natriuretic peptide (NT-proBNP) at week 48. Survival was estimated by Kaplan-Meier analysis, and we estimated hazard ratio (HR) using Co …
We repeated assessments including functional class and 6-min walk distance (6MWD) at 12-week intervals and measured N-terminal pro-brain nat …
Incidence of implantable Collamer lens-induced cataract.
Gimbel HV, LeClair BM, Jabo B, Marzouk H. Gimbel HV, et al. Can J Ophthalmol. 2018 Oct;53(5):518-522. doi: 10.1016/j.jcjo.2017.11.018. Epub 2018 Mar 28. Can J Ophthalmol. 2018. PMID: 30340721
Cataract-free survival with comparison of FDA and non-FDA cohorts was conducted using Kaplan-Meier survival curves with the log-rank test. In addition, covariates adjusted hazards ratios and 95% confidence intervals were calculated using Cox regression. ...
Cataract-free survival with comparison of FDA and non-FDA cohorts was conducted using Kaplan-Meier survival curves with the log-rank …
Intraoperative transfusion practices in Europe.
Meier J, Filipescu D, Kozek-Langenecker S, Llau Pitarch J, Mallett S, Martus P, Matot I; ETPOS collaborators. Meier J, et al. Br J Anaesth. 2016 Feb;116(2):255-61. doi: 10.1093/bja/aev456. Br J Anaesth. 2016. PMID: 26787795 Free PMC article.
The World Health Organization in Global Health Law.
Meier BM, Taylor A, Eccleston-Turner M, Habibi R, Sekalala S, Gostin LO. Meier BM, et al. J Law Med Ethics. 2020 Dec;48(4):796-799. doi: 10.1177/1073110520979392. J Law Med Ethics. 2020. PMID: 33404342 No abstract available.
Unveiling the Prognostic Significance of BCL6+/CD10+ Mantle Cell Lymphoma: Meta-Analysis of Individual Patients and Systematic Review.
Castillo DR, Park D, Jeon WJ, Joung B, Lee J, Yang C, Pham B, Hino C, Chong E, Shields A, Nguyen A, Brothers J, Liu Y, Zhang KK, Cao H. Castillo DR, et al. Int J Mol Sci. 2023 Jun 16;24(12):10207. doi: 10.3390/ijms241210207. Int J Mol Sci. 2023. PMID: 37373354 Free PMC article. Review.
Overall survival (OS) rates were performed by the Kaplan-Meier method and log-rank test. Our analyses revealed that BCL6+ MCL had significantly shorter overall survival (median OS: 14 months vs. 43 months; p = 0.01), BCL6+/CD10+ MCL had an inferior outcome vs. ...
Overall survival (OS) rates were performed by the Kaplan-Meier method and log-rank test. Our analyses revealed that BCL6+ MCL had sig …
173 results